Ann: Investor web conference presentation, 14 July 2023, page-32

Just had a chance to listen now.
What was obvious to me was how often Jon made mention of Fragile-X in his discussion compared to last few years.

Remembering "Neuren has conducted a Phase 2 double-blind placebo-controlled clinical trial in subjects aged 12 to 45 years with Fragile X"

This is definitely back on the table now, the question will be how quickly will Acadia want to run with this, also Jon noting $55m in development milestone payments.

Interesting also he deflected the take-over question and whether there has been interest - he chose to not answer, but as another poster pointed out, chose to read the question....

Maybe Acadia already put that offer on the table but not at a satisfactory level. So they're buying us bit by bit...